Farlan Veraitch’s research focuses on the development of robust, reproducible and cost effective production processes in the emerging field of cell therapy. His team are establishing novel processing technologies which will underpin the commercialisation of these types of products. Their work uses a whole bioprocessing methodology pioneered at UCL to ensure that new production process are considered as whole rather than individual operations in isolation. Using pluripotent stem cells as a model system Farlan’s group are developing new methods for the majority of steps involved in the production of cellular therapies. Current projects include the application of bioprocessing methodologies to (i) the expansion of pluripotent stem cells, (ii) their directed differentiation into regenerative populations, (iii) the non-destructive dissociation of differentiated cellular aggregates into single cell suspensions, (iv) purification techniques for positive selection and (v) point-of-care processing which includes cryopreservation, shipping, thawing, washing and presentation of the final therapy ready for administration. The overall goal of this program of work is to develop platform technologies for the manufacture of stem cell therapies.